MENU
+Compare
ATXS
Stock ticker: NASDAQ
AS OF
Apr 24, 11:50 AM (EDT)
Price
$5.11
Change
-$0.09 (-1.73%)
Capitalization
293.46M

ATXS Astria Therapeutics Forecast, Technical & Fundamental Analysis

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases... Show more

Industry: #Biotechnology
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ATXS with price predictions
Apr 23, 2025

ATXS in +26.52% Uptrend, advancing for three consecutive days on April 23, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ATXS advanced for three days, in of 267 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ATXS's RSI Oscillator exited the oversold zone, of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on April 22, 2025. You may want to consider a long position or call options on ATXS as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ATXS just turned positive on April 22, 2025. Looking at past instances where ATXS's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATXS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ATXS broke above its upper Bollinger Band on April 23, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ATXS entered a downward trend on April 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.310) is normal, around the industry mean (14.056). P/E Ratio (0.000) is within average values for comparable stocks, (63.446). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.788). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (252.992).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ATXS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ATXS is expected to report earnings to rise 2.18% to -44 cents per share on May 08

Astria Therapeutics ATXS Stock Earnings Reports
Q1'25
Est.
$-0.45
Q4'24
Beat
by $0.01
Q3'24
Est.
$-0.42
Q2'24
Missed
by $0.06
Q1'24
Missed
by $0.03
The last earnings report on March 11 showed earnings per share of -43 cents, beating the estimate of -45 cents. With 103.46K shares outstanding, the current market capitalization sits at 293.46M.
A.I. Advisor
published General Information

General Information

a developer of new medicines for the treatment of cardiovascular, metabolic and inflammatory diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
75 State Street
Phone
+1 617 349-1971
Employees
59
Web
https://www.astriatx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GLVNX68.19N/A
N/A
Invesco Global Focus R
GNXAX12.10N/A
N/A
AlphaCentric Robotics and Automation A
RYCTX201.96N/A
N/A
Rydex S&P 500 2x Strategy C
IBARX22.40N/A
N/A
Macquarie Balanced Fund Class R6
LGLUX41.35N/A
N/A
Lord Abbett Growth Leaders R5

ATXS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with TRDA. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
+12.55%
TRDA - ATXS
52%
Loosely correlated
N/A
KYMR - ATXS
52%
Loosely correlated
+6.56%
XENE - ATXS
49%
Loosely correlated
+2.23%
APGE - ATXS
49%
Loosely correlated
+2.93%
DNLI - ATXS
49%
Loosely correlated
+1.85%
More